Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374877 · ClinicalTrials.gov registry record · Phase 1
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT04374877: Completed Phase 1 study, sponsored by Coherus Oncology.
NCT04374877 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 145 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04374877, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Primary Outcome
Evaluation of DLT of CHS-388 as a monotherapy.
Interventions
- DRUG Pembrolizumab
- DRUG Toripalimab
- DRUG CHS-388
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2025-06-05 |
| Phase | Phase 1 |
What the finished NCT04374877 record still lists
NCT04374877 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04374877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04374877 about?
NCT04374877 is a clinical study titled "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors". This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
What is the current status of trial NCT04374877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2020-04-22. Estimated completion is 2025-06-05.
What interventions are being tested in trial NCT04374877?
The interventions under investigation include: Pembrolizumab (DRUG), Toripalimab (DRUG), CHS-388 (DRUG).
Who is sponsoring clinical trial NCT04374877?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04374877's enrollment target sits among peer trials
145 391st of 2000 higher than 1,607 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI